we will use CRISPR/Cas9 genome-editing and single-cell approaches to prove the functional linkage of candidate MegaTrans drivers and hormone-resistance and metastasis. Consistent with the overall goal of our proposed U54 center, these studies will provide insights into the characteristics or epigenetic changes of ER/AR-bound enhancers that are influenced by different microenvironmental cues during the progression from hormone-sensitive to hormone-resistant cancers.
This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-PD-1 antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options as determined by the Investigator. The study will be conducted in 2 parts.
Mailbox Ctrc Regulatory Affairs